2023-07-27 16:03:50 ET
- Vanda Pharmaceuticals press release ( NASDAQ: VNDA ): Q2 GAAP EPS of $0.03.
- Revenue of $46.06M (-28.5% Y/Y).
- 2023 Guidance: Given uncertainties surrounding the U.S. market for HETLIOZ ® for the treatment of Non-24 as a result of the ongoing HETLIOZ ® patent litigation and the at-risk launch of a generic version of HETLIOZ ® , Vanda is unable to provide 2023 financial guidance at this time. Vanda will continue to evaluate its ability to provide financial guidance as the year progresses.
- HETLIOZ ® net product sales will likely decline in future periods, potentially significantly, related to the at-risk launch of a generic version of HETLIOZ ® in the U.S.
For further details see:
Vanda Pharmaceuticals GAAP EPS of $0.03, revenue of $46.06M